Results of a phase 2 single-cohort clinical trial show that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel provides durable remission with long-term persistence in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Original Article: [News] CAR T-cells for relapsed B-cell ALL in children and young adults
NEXT ARTICLE